Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 02 - 17 tags : Phase 2 save search
Altimmune Announces FDA Clearance of AdCOVID™ IND ApplicationEnrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week
Published: 2021-02-17 (Crawled : 15:00) - biospace.com/
ALT | $7.185 -5.09% 610K
|
Commercial Services
|
| O: 3.04%
H: 11.32%
C: 10.5%
covid fda clearance fda adcovid phase 1 vaccine trial phase 3 phase 2 clearance
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Published: 2021-02-17 (Crawled : 15:00) - biospace.com/
NKTR | News | $1.405 -1.06% 180K
|
Health Technology
|
| O: 11.31%
H: 7.0%
C: 1.84%
phase 2 phase 2/3 keytruda cell carcinoma
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Published: 2021-02-17 (Crawled : 15:00) - biospace.com/
KTRA | $0.1311 -1.21% 700K
|
Distribution Services
|
| O: 11.11%
H: 1.15%
C: -3.85%
phase 2 trial enroll
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19
Published: 2021-02-17 (Crawled : 13:11) - prnewswire.com
PTCT | News S | $25.15 -1.02% 99K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: -2.41%
covid treatment phase 2 phase 2/3 trial
Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients
Published: 2021-02-17 (Crawled : 13:00) - globenewswire.com
SLRX | $0.501 13K
|
Commercial Services
|
| O: 9.43%
H: 3.45%
C: -6.9%
phase 1 expansion trial phase 3 phase 2
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Published: 2021-02-17 (Crawled : 12:11) - prnewswire.com
IMUX | $1.23 -0.81% 45K
|
Health Technology
|
| O: -10.32%
H: 1.3%
C: -10.58%
covid treatment phase 2 trial imu-838
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.